[Featured Stock] "Focus on ADC Assets" Rigakem Bio Up Over 8%

The stock price of Ligacymbio, a domestic antibody-drug conjugate (ADC) developer, is on the rise. In the securities industry, Ligacymbio has been identified as the leading domestic company in the ADC therapeutic field, which is expected to reshape the cancer treatment market, and a new buy recommendation has been issued in a corporate report.

As of 10:16 AM on the 7th, Ligacymbio was trading at 90,500 KRW, up 7,100 KRW (8.51%) from the previous trading day.

On the same day, DS Investment & Securities newly issued a buy recommendation for Ligacymbio, stating it is their top preferred stock in the bio industry, and set a target price of 140,000 KRW.

Minjeong Kim, a researcher at DS Investment & Securities, said, "ADC is driving market changes in four of the top five cancer types by sales in the cancer market (lung cancer, breast cancer, prostate cancer, multiple myeloma, lymphoma)." She added, "Additional clinical results for Ligacymbio's ADC compound 'LCB71' are expected to be announced this year. Global demand for LCB71, which has high safety and efficacy, is anticipated to be very strong. Furthermore, significant attention is expected to focus on Ligacymbio's related assets in the future."